SpyGlass Pharma, Inc. filed a Form 8-K on November 12, 2026, reporting its third-quarter 2026 financial results and disclosing that it completed its first implantations in a first-in-human study of its Bimatoprost-Drug Ring System in October 2026.

Key Highlights

  • First-in-human milestone: SpyGlass Pharma completed its first implantations in a first-in-human study of the Bimatoprost-Drug Ring System (BIM-DRS) in October 2026, according to the filing.
  • Device description: The BIM-DRS is described in the filing as "a non-IOL-based sustained drug delivery system for glaucoma designed to deliver up to seven years of bimatoprost."
  • Quarterly results announced: The company issued a press release on November 11, 2026, announcing financial results for the quarter ended September 30, 2026.
  • Emerging growth company: The registrant indicated it is an emerging growth company as defined under applicable SEC rules.
  • Exchange listing: The company's common stock, par value $0.00001 per share, trades on NASDAQ:SGP.

SpyGlass Pharma Reports Q3 2026 Results and BIM-DRS Clinical Study Progress

SpyGlass Pharma, Inc. (NASDAQ:SGP), a Delaware-incorporated company headquartered at 15326 Alton Parkway, Irvine, California 92618, filed a current report on Form 8-K dated November 12, 2026, covering events as of November 11, 2026. The filing addresses two separate items: the company's quarterly financial results and a clinical development update.

Under Item 2.02, the filing disclosed that SpyGlass Pharma issued a press release on November 11, 2026, announcing financial results for the quarter ended September 30, 2026. The press release was furnished as Exhibit 99.1 to the report. As noted in the filing, the information furnished under Item 2.02 and in Exhibit 99.1 "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended," unless expressly incorporated by specific reference in a subsequent filing.

Under Item 8.01, the company disclosed that in October 2026 it completed its first implantations in a first-in-human study of the Bimatoprost-Drug Ring System, referred to as BIM-DRS. The filing describes BIM-DRS as a non-IOL-based sustained drug delivery system for glaucoma, designed to deliver up to seven years of bimatoprost. The report was signed by Jean-Frederic Viret, Ph.D., Chief Financial Officer, on November 12, 2026.

What Was Disclosed

SpyGlass Pharma's Form 8-K reported Q3 2026 financial results via a press release and disclosed that first-in-human implantations of its BIM-DRS glaucoma drug delivery device were completed in October 2026, with the device designed to deliver up to seven years of bimatoprost.